Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 01, 2016 16:05 ET | Source: Vitae Pharmaceuticals, Inc.

Vitae Pharmaceuticals to Present at Wells Fargo Healthcare Conference

FORT WASHINGTON, Pa., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that Jeffrey Hatfield, President and Chief...
August 11, 2016 07:30 ET | Source: Vitae Pharmaceuticals, Inc.

Vitae Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference

FORT WASHINGTON, Pa., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that Jeffrey Hatfield, President and Chief...
August 10, 2016 16:05 ET | Source: Vitae Pharmaceuticals, Inc.

Vitae Pharmaceuticals Appoints Scott Applebaum as General Counsel and Corporate Secretary

FORT WASHINGTON, Pa., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced the appointment of Scott Applebaum as...
August 03, 2016 16:05 ET | Source: Vitae Pharmaceuticals, Inc.

Vitae Pharmaceuticals Reports Second Quarter 2016 Operating and Financial Results

Proof-of-concept data for VTP-38543 expected in the fourth quarter of 2016 Conference call scheduled for 4:30 p.m. EDT today FORT WASHINGTON, Pa., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Vitae...
August 01, 2016 17:30 ET | Source: Vitae Pharmaceuticals, Inc.

Vitae Pharmaceuticals to Announce Second Quarter 2016 Financial Results on August 3, 2016

FORT WASHINGTON, Pa., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, will host a conference call on Wednesday, August 3, 2016 at...
July 27, 2016 16:30 ET | Source: Vitae Pharmaceuticals, Inc.

Vitae Pharmaceuticals Appoints Daniel M. Junius to Board of Directors

FORT WASHINGTON, Pa., July 27, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced the appointment of Daniel M. Junius to its...
June 14, 2016 16:05 ET | Source: Vitae Pharmaceuticals, Inc.

Vitae Pharmaceuticals to Present at JMP Securities Life Sciences Conference

FORT WASHINGTON, Pa., June 14, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that Richard Gregg, M.D., Chief Scientific...
June 06, 2016 16:05 ET | Source: Vitae Pharmaceuticals, Inc.

Vitae Pharmaceuticals Announces Appointment of Carole Sable, M.D., as Chief Medical Officer

FORT WASHINGTON, Pa., June 06, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that Carole Sable, M.D., has been named...
May 10, 2016 16:01 ET | Source: Vitae Pharmaceuticals, Inc.

Vitae Pharmaceuticals Reports First Quarter 2016 Operating and Financial Results

Proof-of-concept data for VTP-38543 expected in the second half of 2016Conference call scheduled for 4:30 p.m. EDT todayFORT WASHINGTON, Pa., May 10, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals,...
May 09, 2016 16:30 ET | Source: Vitae Pharmaceuticals, Inc.

Vitae Pharmaceuticals to Present at IMMUNOLOGY 2016

Poster to highlight positive Phase 1 data for RORγt inhibitor VTP-43742 FORT WASHINGTON, Pa., May 09, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage...